Healio: Percutaneous ventricular assist devices yield similar periprocedural outcomes in high-risk PCI Please provide your email address to receive an email when new articles are posted on . A new meta-analysis highlights similar periprocedural outcomes between two percutaneous ventricular assist ... Supira Medical announced today that it received FDA approval to initiate a new trial of its percutaneous ventricular assist device (pVAD).
CNW/ -- (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, ... Medical Xpress: Successful cardiogenic shock treatment using a percutaneous left ventricular assist device EurekAlert!: Novel percutaneous ventricular assist device feasibile in patients undergoing high-risk percutaneous coronary interventions (HRPCI) Phoenix, AZ, () - Findings from the first-in-human trial of a novel percutaneous ventricular assist device (pVAD) were presented today as late-breaking clinical research at the Society for ... Novel percutaneous ventricular assist device feasibile in patients undergoing high-risk percutaneous coronary interventions (HRPCI) FOX59 News: SUPIRA MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS NEXT GENERATION PERCUTANEOUS VENTRICULAR ASSIST DEVICE SUPIRA MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS NEXT GENERATION PERCUTANEOUS VENTRICULAR ASSIST DEVICE PharmiWeb: Global Ventricular Assist Devices Market to Grow at 11% CAGR, Driven by Heart Failure Cases by 2030 The global ventricular assist devices (VAD) market is projected to grow at a CAGR of ~11% during the forecast period. This growth is primarily driven by the rising prevalence of heart failure, the ...
